Methionine sulfoxide reductase system: Possible roles in protection against neurodegenerative diseases

Oxidative Stress and Age-Related Neurodegeneration

Volumn , Issue , 2005, Pages 199-212

  Moskovitz, Jackob ^a   Bush, Ashley I ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35348906893     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (79)

1. Moskovitz J, Poston M, Berlett BS, Nosworthy JN, Szczepanowski R, Stadtman, ER. Identification and characterization of a putative active site for peptide-methio-nine sulfoxide reductase (MsrA) and its substrate stereospecificity. J Biol. Chem, 2000; 275: 14167-14172.
2. Moskovitz J, Singh VK, Requena J, Wilkinson BJ, Jayaswal RK, Stadtman, ER. Purification and characterization of methionine sulfoxide reductases from mouse and Staphylococcus aureus and their substrate stereospecificity. Biochem Biophys Res Commun, 2002; 290: 62-65.
3. Moskovitz J, Rahman MA, Strassman J, Yancey SO, Kushner SR, Brot N, Weissbach H. Escherichia coli peptide methionine sulfoxide reductase gene regulation of expression and role in protecting against oxidative damage. J Bacteriol, 1995; 177: 502-507.
4. Moskovitz J, Berlett SB, Poston M, Stadtman ER. The yeast peptide-methionine sulfoxide reductase functions as an antioxidant in-vivo. Proc Natl Acad Sci USA, 1997; 94: 9585-9589.
5. Moskovitz J, Bar-Noy S, Williams W, Requena J, Berlett BS, Stadtman ER. Methionine sulfoxide reductase (MsrA) is a regulator of antioxidant defense and life span in mammals. Proc Natl Acad Sci USA, 2001; 98: 2920-12925.
6. Romero HM, Berlett BS, Jensen PJ, Pell EJ, Tien M. Investigations into the role of the plastidial Peptide methionine sulfoxide reductase in response to oxidative stress in Arabidopsis. Plant Physiol, 2004; 136: 3784-3794.
7. Moskovitz J, Flescher E, Berlett SB, Azare JA, Poston M, Stadtman ER. Overexpression of peptide-methionine sulfoxide reductase (MsrA) in Saccaromyces cerevisiae and human T cells provides them with high resistance to oxidative stress. Proc Natl Acad Sci USA, 1998; 95: 14071-14075.
8. Ruan H, Tang XD, Chen ML, Joiner ML, Sun G, Brot N, Weissbach H, Heinemann SH, Iverson L, Wu CF, Hoshi T, Chen ML, Joiner MA, Heinemann SH. High-quality life extension by the enzyme peptide methionine sulfoxide reductase. Proc Natl Acad Sci USA, 2002; 99: 2748-2753.
9. Moskovitz J, Stadtman ER. Selenium deficient diet enhances protein oxidation and affects methionine sulfoxide reductase (MsrB) protein level in certain mice tissues. Proc Natl Acad Sci USA, 2003; 100: 7486-7490.
10. Gabbita SP, Aksenov MY, Lovell MA, Markesbery WR. Decrease in peptide methionine sulfoxide reductase in Alzheimer’s disease brain. J Neurochem, 1999; 73: 1660-1666.
11. Uversky VN, Yamin G, Souillac PO, Goer J, Glaser CB, Fink AL. Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett, 2002; 517: 239-244.
12. Hou L, Kang I, Marchant RE, Zagorski MG. Methionine 35 oxidation reduces fibril assembly of the amyloid abeta-(1-42) peptide of Alzheimer’s disease. J Biol Chem, 2003; 177: 40173-40176.
13. Yamin G, Glaser CB, Uversky VN, Fink AL. Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. J Biol Chem, 2003; 278: 27630-27635.
14. Varadarajan S. Yatin S, Kanski J, Jahanshahi F, Butterfield DA. Methionine residue 35 is important in amyloid beta-peptide-associated free radical oxidative stress. Brain Res Bull, 1999; 50: 133-141.
15. Schoneich C. Redox processes of methionine relevant to beta-amyloid oxidation and Alzheimer’s disease. Arch Biochem Biophys, 2002; 397: 370-376.
16. Pogocki D. Alzheimer’s beta-amyloid peptide as a source of neurotoxic free radicals: the role of structural effects. Acta Neurobiol Exp (Wars), 2003; 63: 131-145.
17. Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G, Carey PR. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry, 2003; 42(10): 2768-2773.
18. Manning-Bog AB, McCormack AL, Purisai MG, Bolin LM, Di Monte DA. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. JNeurosci, 2003; 23: 3095-3099.
19. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson’s disease. Science, 2003; 302: 841.
20. Li W, Lesuisse C, Xu Y, Troncoso JC, Price DL, Lee MK. Stabilization of alpha-synuclein protein with aging and familial parkinson’s disease-linked A53T mutation. J Neurosci, 2004; 24(33): 7400-7409.
21. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer’s disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J, 1985; 4: 2757-2763.
22. Selkoe DJ, Podlisny MB, Gronbeck A, Mammen A, Kosik KS. Molecular relation of amyloid filaments and paired helical filaments in Alzheimer’s disease. Adv Neurol, 1990; 51: 171-179.
23. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature, 1992; 359: 322-325.
24. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C. Isolation and quantification of soluble Alzheimer’s P-peptide from biological fluids. Nature, 1992; 359: 325-327.
25. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai X-D, McKay DM, Tintner R, Frangione B, Younkin SG. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science, 1992; 258: 126-129.
26. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature, 1987; 325:733-736.
27. Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer’s disease. Science, 1987; 235: 877-880.
28. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ. Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat Med, 1997; 3: 67-72.
29. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature, 1999; 398: 513-517.
30. Prelli F, Castaño E, Glenner GG, Frangione B. Differences between vascular and plaque core amyloid in Alzheimer’s disease. J Neurochem, 1988; 51: 648-651.
31. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, Reardon IM, Zurcher-Neely HA, Heinrikson RL, Ball MJ. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer’s disease. J Biol Chem, 1993; 268: 3072-3083.
32. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Jr., Eckman C, Golde TE, Younkin SG. An increased percentage of long amyloid P protein secreted by familial amyloid β protein precursor (beta APP717) mutants. Science, 1994; 264: 1336-1340.
33. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med, 1996; 2: 864-870.
34. Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer’s disease. J Mol Biol, 1991; 218: 149-163.
35. Jarrett JT, Berger EP, Lansbury PT, Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry, 1993; 32: 4693-4697.
36. McLean C, Cherny R, Fraser F, Fuller S, Smith M, Beyreuther K, Bush A, Masters C. Soluble pool of AP amyloid as a determinant of severity of neurodegeneration in Alzheimer’s Disease. Ann Neurol, 1999; 46: 860-866.
37. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, Woods AS, Cotter RJ, Tuohy JM, Krafft GA, Bonnell BS, Emmerling MR. Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer’s disease. J Biol Chem, 1996; 271: 20631-20635.
38. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA, 1998; 95: 6448-6453.
39. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 2002; 416: 535-539.
40. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry, 2000; 39: 10831-10839.
41. Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Aggregation and secondary structure of synthetic amyloid β A4 peptides of Alzheimer’s disease. J Mol Biol, 1991; 218: 149-163.
42. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases oxidative stress. Nat Rev Drug Discov, 2004; 3: 205-214.
43. Omar RA, Chyan YJ, Andorn AC, Poeggeler B, Robakis NK, Pappolla MA. Increased expression but reduced activity of antioxidant enzymes in Alzheimer’s disease. J Alzheimers Dis, 1999; 3: 139-145.
44. Pappolla MA, Omar RA, Kim KS, Robakis NK. Immunohistochemical evidence of oxidative stress in Alzheimer’s disease. Am J Pathol, 1992; 140: 621-628.
45. Aksenov MY, Tucker HM, Nair P, Aksenova MV, Butterfield DA, Estus S, Markesbery WR. The expression of key oxidative stress-handling genes in different brain regions in Alzheimer’s disease. J Mol Neurosci, 1998; 11: 151-164.
46. 2. J Biol Chem, 2002; 277: 40302-40308.
47. Barnham KJ, Haeffner F, Ciccotosto GD, Curtain CC, Tew D, Mavros C, Beyreuther K, Carrington D, Masters CL, Cherny RA, Cappai R, Bush AI. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer’s disease beta-amyloid. FASEB J, 2004; 18(12): 1427-1429.
48. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid ß protein toxicity. Cell, 1994; 77: 817-827.
49. Bruce AJ, Malfroy B, Baudry M. Beta-Amyloid toxicity in organotypic hippocampal cultures: protection by Euk-8, a synthetic catalytic free radical scavenger. Proc Natl Acad Sci USA, 1996; 93: 2312-2316.
50. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall J, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Moir RD, Glabe C, Bowden EF, Masters CL, Fairlie DP, Tanzi RE, Bush AI. Cu(II) potentiation of Alzheimer Aß neurotoxicity: correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem, 1999; 274: 37111-37116.
51. Rottkamp C, Raina A, Zhu X, Gaier E, Bush A, Atwood C, Chevion M, Perry G, Smith M. Redox-active iron mediates amyloid-ß toxicity. Free Rad Biol Med, 2001; 30: 447-450.
52. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci, 2001; 21: 8370-8377.
53. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med, 1997; 336: 1216-1222.
54. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol, 2000; 59: 1011-1017.
55. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol, 2001; 60: 759-767.
56. Sung S, Yao Y, Uryu K, Yang H, Lee VM, Trojanowski JQ, Pratico D. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer’s disease. FASEB J, 2004; 18: 323-325.
57. Li F, Calingasan NY, Yu F, Mauck WM, Toidze M, Almeida CG, Takahashi RH, Carlson GA, Flint Beal M, Lin MT, Gouras GK. Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J Neurochem, 2004; 89: 1308-1312.
58. Malfroy B, Doctrow SR, Orr PL, Tocco G, Fedoseyeva EV, Benichou G. Prevention and suppression of autoimmune encephalomyelitis by EUK-8, a synthetic catalytic scavenger of oxygen-reactive metabolites. Cell Immunol, 1997; 177: 62-68.
59. Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer’s disease from normal and pathologic aging. Exp Neurol, 1999; 158: 328-337.
60. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol, 1999; 155: 853-862.
61. Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, Glabe C. Oxidation of Abeta and plaque biogenesis in Alzheimer’s disease and Down syndrome. Neurobiol Dis, 2001; 8: 792-806.
62. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S. Dominant and differential deposition of distinct ß-amyloid peptide species, Aß N3(pE), in senile plaques. Neuron, 1995; 14: 457-466.
63. Atwood CS, Huang X, Kahtri A, Scarpa RC, Moir RD, Kim Y-S, Tanzi RE, Roher AE, Bush AI. Copper catalyzed oxidation of Alzheimer Aβ. Cell Mol Biol, 2000; 46: 777-783.
64. Watson AA, Fairlie DP, Craik DJ. Solution structure of methionine-oxidized amyloid beta-peptide (1-40). Does oxidation affect conformational switching? Biochemistry, 1998; 37: 12700-12706.
65. Frederikse PH, Garland D, Zigler JS, Piatigorsky J. Oxidative stress increases production of β-amyloid precursor protein and β -amyloid (A-beta) in mammalian lenses, and A-beta has toxic effects on lens epithelial cells. J Biol Chem, 1996; 271: 10169-10174.
66. Misonou H, Morishima-Kawashima M, Ihara Y. Oxidative stress induces intracellular accumulation of amyloid beta- protein (Abeta) in human neuroblastoma cells. Biochemistry, 2000; 39: 6951-6959.
67. Barnham KJ, Ciccotosto GD, Tickler AK, Ali FE, Smith DG, Williamson NA, Lam YH, Carrington D, Tew D, Kocak G, Volitakis I, Separovic F, Barrow CJ, Wade JD, Masters CL, Cherny RA, Curtain CC, Bush AI, Cappai R. Neurotoxic, redox-competent Alzheimer’s beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem, 2003; 278(44): 42959-42965
68. Moskovitz J, Weissbach H, Brot N. Cloning the expression of a mammalian gene involved in the reduction of methionine sulfoxide residues in proteins. Proc Natl Acad Sci USA, 1996; 93(5): 2095-2099.
69. Jackson GS, Hosszu LL, Power A, Hill AF, Kenney J, Saibil H, Craven CJ, Waltho JP, Clarke AR, Collinge J. Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science, 1999; 283: 1935-1937.
70. Vassallo N, Herms J. Modulation of L-type voltage-gated calcium channels by recombinant prion protein. J Neurochem, 2003; 86: 538-542.
71. Brown DR. Prion protein expression modulates neuronal copper content. Neurochemistry, 2003; 87: 377-385.
72. Hill AF, Joiner S, Wadsworth JD, Sidle KC, Bell JE, Budka H, Ironside JW, Collinge J. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain, 2003; 126: 1333-1346.
73. Erginel-Unaltuna N, Peoc’h K, Komurcu E, Acuner TT, Issever H, Laplanche JL. Distribution of the M129V polymorphism of the prion protein gene in a Turkish population suggests a high risk for Creutzfeldt-Jakob disease. Eur J Hum Genet, 2001; 9: 965-968.
74. Bratosiewicz J, Liberski PP, Kulczycki J, Kordek R. Codon 129 polymorphism of the PRNP gene in normal Polish population and in Creutzfeldt-Jakob disease, and the search for new mutations in PRNP gene. Acta Neurobiol Exp (Wars), 2001; 61: 151-156.
75. Wong BS, Wang H, Brown DR, Jones IM. Selective oxidation of methionine residues in prion proteins. Biochem Biophys Res Commun, 1999; 259: 352-355.
76. Requena JR, Groth D, Legname G, Stadtman ER, Prusiner SB, Levine RL. Copper-catalyzed oxidation of the recombinant SHa(29-231) prion protein. Proc Natl Acad Sci USA, 2001; 98: 7170-7175.
77. Wong BS, Chen SG, Colucci M, Xie Z, Pan T, Liu T, Li R, Gambetti P, Sy MS, Brown DR. Aberrant metal binding by prion protein in human prion disease, J Neurochem, 2001; 78: 1400-1408.
78. Rachidi W, Vilette D, Guiraud P, Arlotto M, Riondel J, Laude H, Lehmann S, Favier A. Expression of prion protein increases cellular copper binding and antioxidant enzyme activities but not copper delivery. J Biol Chem, 2003; 278: 9064-9072.
79. c in mouse cerebral microvessels and brain parenchyma. Neuropathol Appl Neurobiol, 2004; 30: 161-168.